<DOC>
	<DOC>NCT01349010</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of imported Probucol in hyperlipidemia patients.</brief_summary>
	<brief_title>Efficacy and Safety of Imported Probucol to Treat Hyperlipidemia</brief_title>
	<detailed_description>This is a randomized, double blind, placebo control, multi-centre clinical study in hyperlipidemia patients. Enrolled subjects will be randomized to the treatment group or control group, and receive Probucol or placebo continuously for 8 weeks; Treatment group: Imported Probucol 250 mg (1 tablet) bid. p.o Control group: Placebo 1 tablet bid. p.o</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Probucol</mesh_term>
	<criteria>1. Signing Informed Content Form; 2. Age &gt;= 20 (the age at the time of signing ICF; both gender); 3. hyperlipidemia patients who meet the following criteria: 4.14 mmol/L (160mg/dL) =&lt; LDLC (Serum low density lipoproteincholesterol) &lt; 6 mmol/L (232mg/dL) TG (Serum triglycerides) &lt; 4.5 mmol/L (398mg/dL); 4. Framingham: Coronary Heart Disease 2year risk probabilities &lt; 10%. 1. Subjects who receive antilipemic agents within 1 month prior to the prescreening period; 2. Subjects who receive Probucol within 6 months prior to the prescreening period; 3. Coronary Heart Disease subjects; 4. Subjects being treated with cyclosporine; 5. Subjects with a history of hypersensitivity to Probucol; 6. QTc interval &gt; 450ms (male); QTc interval &gt; 470ms (female); 7. Subjects with impaired hepatic and renal function, who meet any of the following abnormal value: AST &gt;= 100IU/L ALT &gt;= 100IU/L Serum creatinine &gt;= 1.5mg/dL 8. Female subjects who are pregnant, lactating, or who plan to conceive; 9. Subjects who are considered by the investigator to be inappropriate to participate in this trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>hyperlipidemia</keyword>
</DOC>